GlassScriptPhysician profile
William D Kernodle
NPI 1699765024
$14,122.33
in general payments reported to CMS, 2019-2025
35 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,376 · 2021: $2,083 · 2022: $1,978 · 2023: $2,446 · 2024: $2,378 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,453 · Education: $28.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,453.28 |
| Education | $28.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,582.98 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,367.46 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,037.50 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $1,023.42 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $902.80 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $761.16 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $758.98 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $746.15 | 2022-2025 | Caplyta |
| Corium, LLC | $740.26 | 2022-2025 | Azstarys, Adlarity |
| Lundbeck LLC | $620.13 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $575.12 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $482.88 | 2019-2025 | Dyanavel Xr |
| Alkermes, INC. | $464.51 | 2021-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $421.24 | 2022-2025 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $328.83 | 2022-2025 | Auvelity, Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $301.98 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $293.60 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $239.13 | 2025 | Cobenfy |
| Allergan, INC. | $207.53 | 2019-2020 | |
| Eisai INC. | $179.15 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $165.58 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $161.33 | 2021-2024 | Secuado, Xelstrym |
| Shire North American Group INC | $122.35 | 2019 | |
| Neuronetics, INC. | $107.00 | 2020-2025 | Neurostar Tms Therapy System |
| Neos Therapeutics, LP | $104.52 | 2020-2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $72.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $68.62 | 2019-2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $48.60 | 2021-2022 | |
| Harmony Biosciences LLC | $47.61 | 2025 | |
| Vertical Pharmaceuticals, LLC | $45.14 | 2019-2020 | |
| Adlon Therapeutics L.P. | $41.01 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.60 | 2023-2024 | Quviviq |
| Alfasigma USA, INC. | $35.30 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.07 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kernodle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.